지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2003.12
- 수록면
- 160 - 168 (9page)
이용수
초록· 키워드
오류제보하기
Objectives : Risperidone and olanzapine, which are atypical antipsychotics, are widely used in the treatment of schizophrenia as the 1st line drug, proving their effectiveness for both positive and negative symptoms. They also have many advantages even from the side effects. However, they show differences with the chemical structure and pharmacokinetics and they work differently to receptors. Researchers have studied the effect and side effect during the acute phase of schizophrenia as an open prospective study.
Methods : Forty subjects with DSM-Ⅳ schizophrenia or schizoaffective patients including 1) 1st onset schizophrenia patient, 2) patient who has been treated by the prior antipsychotics and not improved or even worse to be admitted again, were assigned to receive risperidone or olanzapine for 6 weeks. Psychopathology, adverse effect, weight change, fasting serum glucose, and drug cost were compared within and across groups.
Results : After 6 weeks later both treatment groups showed the significant decrease in PANSS positive, general psychopathology and total score while they did not show any significant difference between two groups. Risperidone group, however, showed the significant decrease in PANSS negative score, which olanzapine group did not. In terms of adverse effect risperidone group showed more extrapyramidal symptom than olanzapine group. Body weight rised significantly after 6weeks, but no significant difference between two treatment groups. There were no significant increase of fasting serum glucose level.
Conclusions : Risperidone and olanzapine are effective drugs which can be used during the acute phase of schizophrenia. Risperidone is expected to shorten the admission day and remission of the symptom of acute phase, while olanzapine is more advantage in a neurologic side effect than risperidone.
Methods : Forty subjects with DSM-Ⅳ schizophrenia or schizoaffective patients including 1) 1st onset schizophrenia patient, 2) patient who has been treated by the prior antipsychotics and not improved or even worse to be admitted again, were assigned to receive risperidone or olanzapine for 6 weeks. Psychopathology, adverse effect, weight change, fasting serum glucose, and drug cost were compared within and across groups.
Results : After 6 weeks later both treatment groups showed the significant decrease in PANSS positive, general psychopathology and total score while they did not show any significant difference between two groups. Risperidone group, however, showed the significant decrease in PANSS negative score, which olanzapine group did not. In terms of adverse effect risperidone group showed more extrapyramidal symptom than olanzapine group. Body weight rised significantly after 6weeks, but no significant difference between two treatment groups. There were no significant increase of fasting serum glucose level.
Conclusions : Risperidone and olanzapine are effective drugs which can be used during the acute phase of schizophrenia. Risperidone is expected to shorten the admission day and remission of the symptom of acute phase, while olanzapine is more advantage in a neurologic side effect than risperidone.
목차
영어 초록
서론
대상 및 방법
결과
고찰
참고문헌
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
만성 정신분열병 및 분열정동장애 환자에서 Risperidone, Olanzapine 그리고 Quetiapine의 치료 효과와 안정성에 대한 전향적 비교 연구
생물치료정신의학
2004 .12
-
Clozapine과 Risperidone에서 Olanzapine으로 교체 연구 : 12개월 추적연구
생물정신의학
2001 .01
-
정신분열병 환자에서 Olanzapine이 인지기능에 미치는 영향
생물치료정신의학
2001 .06
-
Adjunctive Risperidone and Olanzapine in the Treatment of Patients with Bipolar I Disorder :A Retrospective Study
Clinical Psychopharmacology and Neuroscience
2005 .01
-
만성정신분열증 환자에 대한 리스페리돈 장기투여 2례
생물치료정신의학
1995 .12
-
리스페리돈과 올란자핀으로 치료한 정신분열병 입원환자의 1년 추적 조사 : 비용-경제적 측면
신경정신의학
2002 .12
-
Olanzapine에 의해 당뇨병성 케톤산증으로 진행한 환자 1예
신경정신의학
2007 .01
-
Olanzapine-induced Orthostatic Hypotensio
Clinical Psychopharmacology and Neuroscience
2015 .01
-
리스페리돈과 올란자핀이 투여된 정신과 환자들에서 간 효소 변화에 대한 후향적 연구
신경정신의학
2004 .01
-
올란자핀의 체중증가 부작용 발생율 및 체중변화량
약학회지
2008 .01
-
소아 청소년 정신과 입원 환자에서 Risperidone의 효과 및 안정성에 관한 연구
소아청소년정신의학
2005 .09
-
정신분열병의 급성 치료에서 리스페리돈과 할로페리돌의 치료 효과와 추체외로 부작용
생물치료정신의학
2000 .06
-
2회의 임신 전 기간 동안 Olanzapine을 사용한 분열정동장애 환자 : 각각 생후 35개월과 14개월 나이 때까지의 추적관찰
생물치료정신의학
2008 .12
-
G-protein β3 Subunit Gene 825C/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients
PSYCHIATRY INVESTIGATION
2009 .01
-
급성 정신분열병 환자에 대한 Risperidone(R 64766)의 임상 효과 및 안정성 연구
한국응용약물학회 신약개발 연구발표회
1993 .01
-
정신분열병 환자의 인지기능에 대한 올란자핀 약물치료의 효과
신경정신의학
2003 .01
-
리스페리돈(Risperidone)을 투약 중인 정신분열병 환자에서 지프라시돈(Ziprasidone)으로 교체 투약 시 보이는 임상적 및 대사적 이득에 대한 전향적 개방 연구
생물치료정신의학
2009 .06
-
정신분열병 환자에서 비정형 항정신병 약물이 프로락틴과 테스토스테론 농도에 미치는 영향
생물정신의학
2000 .01
-
Olanzapine Attenuates Mechanical Allodynia in a Rat Model of Partial Sciatic Nerve Ligation
The Korean Journal of Pain
2015 .01
-
BIOEQUIVALENCE EVALUATION OF RISPERIDONE 2 MG TABLETS IN HEALTHY MALE KOREAN VOLUNTEERS
대한약학회 학술대회
2003 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2009-513-017219311